0.912
0.09 (10.51%)
| Penutupan Terdahulu | 0.825 |
| Buka | 0.832 |
| Jumlah Dagangan | 318,625 |
| Purata Dagangan (3B) | 219,470 |
| Modal Pasaran | 81,801,256 |
| Harga / Buku (P/B) | 0.720 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 7 May 2025 |
| EPS Cair (TTM) | -0.280 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.21% |
| Nisbah Semasa (MRQ) | 48.80 |
| Aliran Tunai Operasi (OCF TTM) | -15.22 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -36.90 M |
| Pulangan Atas Aset (ROA TTM) | -38.01% |
| Pulangan Atas Ekuiti (ROE TTM) | -55.59% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menurun |
| Biotechnology (Global) | Bercampur | Menurun | |
| Stok | Context Therapeutics Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 5.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 2.0 |
| Purata | 1.88 |
|
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of innovative therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 ("CLDN6") x anti-CD3 bispecific antibody ("bsAb") that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 2.33% |
| % Dimiliki oleh Institusi | 79.93% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Mpm Bioimpact Llc | 31 Mar 2025 | 14,705,882 |
| Avidity Partners Management Lp | 31 Mar 2025 | 7,477,200 |
| Nextech Invest, Ltd. | 31 Mar 2025 | 7,419,355 |
| Nextech Invest Ltd. | 31 Dec 2024 | 7,419,355 |
| Great Point Partners I Lp | 31 Mar 2025 | 4,683,711 |
| Blackstone Inc. | 31 Mar 2025 | 2,440,330 |
| Sio Capital Management, Llc | 31 Mar 2025 | 1,328,352 |
| Ally Bridge Group (Ny) Llc | 31 Mar 2025 | 1,157,448 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 9.00 (D. Boral Capital, 886.95%) | Beli |
| Median | 6.50 (612.80%) | |
| Rendah | 4.00 (Piper Sandler, 338.65%) | Beli |
| Purata | 6.50 (612.80%) | |
| Jumlah | 2 Beli | |
| Harga Purata @ Panggilan | 0.712 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Piper Sandler | 26 Jun 2025 | 4.00 (338.64%) | Beli | 0.651 |
| D. Boral Capital | 08 May 2025 | 9.00 (886.95%) | Beli | 0.773 |
| 29 Apr 2025 | 9.00 (886.95%) | Beli | 0.881 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 02 Jun 2025 | Pengumuman | Context Therapeutics Announces CTIM-76 Trial in Progress Poster Presentation at 2025 ASCO Meeting |
| 29 May 2025 | Pengumuman | Context Therapeutics to Appoint Dr. Karen Chagin, M.D. as Chief Medical Officer |
| 12 May 2025 | Pengumuman | Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 07 May 2025 | Pengumuman | Context Therapeutics Reports First Quarter 2025 Operating and Financial Results |
| 05 May 2025 | Pengumuman | Context Therapeutics Announces Chief Medical Officer Transition |
| 30 Apr 2025 | Pengumuman | Context Therapeutics Presents Preclinical and Translational Data for CT-95, a Mesothelin Targeting T Cell Engager, at 2025 AACR Annual Meeting |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |